Characteristics of kidney transplant outpatients from nephrology department, Hue Central hospital: A single-center study

Vo Tam, Phan Ngoc Tam, To Huu Thien

Nội dung chính của bài viết

Tóm tắt

Kidney transplantation (KTx) is the optimal treatment for improving survival and quality of life for end-stage renal disease (ESRD) patients. A total of 289 kidney transplant recipients were followed in Nephrology Department, Hue Central Hospital, with a significant male predominance (73.36%). The mean age of the cohort was 41.6±11.27 years old, with most patients being between 20 and 40 years old. Among our study cohort, many patients maintained long-term graft function, with 199 patients (n= 68.86%) having a graft survival period of 2-5 years, and 73 patients maintaining graft function for more than 5 years. The average estimated glomerular filtration rate (eGFR) was 54.74±15.56 ml/min/1.73m2, with a corresponding serum creatinine level of 113.9±79.22 μmol/L. Metabolic complications were prevalent in the post-transplant period. Hyperglycemia was observed in 35.89% (n=103) of patients, dyslipidemia in 32.4% (n=93), and hyperuricemia in 46.34% (n=133). Post-transplant anemia (PTA) affected 24.74% (n=71) of patients with similar proportions across genders. Notably, post-transplant erythrocytosis (PTE) was found in 12.2% (n=35) of the cohort, with all affected patients being male. Our observational retrospective study indicates that metabolic-related and hematological complications are common in kidney transplant recipients. Improved management of these complications should be a key focus in post-transplant follow-up care.

Chi tiết bài viết

Tài liệu tham khảo

1. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2011; 11(10): 2093-2109. doi:10.1111/j.1600-6143.2011.03686.x.
2. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013; 369(13): 1215-1226. doi:10.1056/NEJMoa1302506.
3. Simforoosh N, Shemshaki H, Nadjafi-Semnani M, Sotoudeh M. Living related and living unrelated kidney transplantations: A systematic review and meta-analysis. World J Transplant. 2017; 7(2): 152-160. doi:10.5500/wjt.v7.i2.152.
4. Nguyen VL, Quang NN, Hai DV, Minh TT, Quang TL. Cadaveric kidney transplantation from 2010-2020 at Viet Duc University Hospital: our experience from Vietnam, a developing country. Korean J Transplant. 2022; 36(1): S20-S20. doi:10.4285/ATW2022.F-1057.
5. Cheung CY, Tang SCW. Personalized immunosuppression after kidney transplantation. Nephrology. 2022; 27(6): 475-483. doi:10.1111/nep.14035.
6. Malyszko J, Basak G, Batko K, et al. Haematological disorders following kidney transplantation. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2022; 37(3): 409-420. doi:10.1093/ndt/gfaa219.
7. Kanbay M, Siriopol D, Guldan M, et al. Prognostic impact of post-transplant diabetes mellitus in kidney allograft recipients: a meta-analysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2025; 40(3): 554-576. doi:10.1093/ndt/gfae185.
8. Alberti KGMM, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005; 366(9491): 1059-1062. doi:10.1016/S0140-6736(05)67402-8.
9. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016; 15(4): 457-465. doi:10.1517/14740338.2016.1140743.
10. Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol CJASN. 2009; 4(2): 481-508. doi:10.2215/CJN.04800908.
11. Hussain A, Culliford A, Phagura N, Evison F, Gallier S, Sharif A. Comparing survival outcomes for kidney transplant recipients with pre-existing diabetes versus those who develop post-transplantation diabetes. Diabet Med J Br Diabet Assoc. 2022; 39(2): e14707. doi:10.1111/dme.14707.
12. Lin H, Yan J, Yuan L, et al. Impact of diabetes mellitus developing after kidney transplantation on patient mortality and graft survival: a meta-analysis of adjusted data. Diabetol Metab Syndr. 2021; 13(1): 126. doi:10.1186/s13098-021-00742-4.
13. Chowdhury TA, Wahba M, Mallik R, et al. Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation. Diabet Med J Br Diabet Assoc. 2021; 38(6): e14523. doi:10.1111/dme.14523.
14. Warden BA, Duell PB. Management of dyslipidemia in adult solid organ transplant recipients. J Clin Lipidol. 2019; 13(2): 231-245. doi:10.1016/j.jacl.2019.01.011.
15. Iannuzzo G, Cuomo G, Di Lorenzo A, et al. Dyslipidemia in Transplant Patients: Which Therapy? J Clin Med. 2022; 11(14): 4080. doi:10.3390/jcm11144080.
16. Mickiewicz A, Żegleń S, Kędzierska-Kapuza K, et al. Lipid-lowering agents in solid organ transplant recipients. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2025; 40(9): 1659-1671. doi:10.1093/ndt/gfaf104.
17. Malyszko J, Glowinska I, Mysliwiec M. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression? Transplant Proc. 2012; 44(10): 3013-3016. doi:10.1016/j.transproceed.2012.06.070.